Notable insiders, not just any insiders but the ones that we identify as notable purchases continue to outperform the indices. The Nasdaq composite was down 2.10% while the S&P was down 1.39% and the RSP was up 0.33%. My gut feel is there is a pattern underway. The hyperscalers building out the AI infrastructure are getting penalized, SAS Armageddon continues unabetted, and mainstream slow growth industrial and consumer stalwarts are beginning to benefit from their AI efficiency gains.
Name: Timothy R. Barakett
Position: Director
Transaction Date: 02-09-2026 Shares Bought: 50,000 shares an average price paid of $104.93 for Cost: $5,246,500
Company: KKR & Co. Inc. (KKR)
KKR & Co. Inc. is a private equity and real estate investment corporation focused on direct and fund-of-fund investments. It focuses on acquisitions, leveraged buyouts, management buyouts, credit special situations, growth equity, mature, mezzanine, distressed, turnaround, lower middle market, and medium market investments. The firm considers investments in all industries, with a particular emphasis on software, fintech, data and information, security, semiconductors, consumer electronics, the internet of things, information services, information technology infrastructure, financial technology, network and cyber security architecture, engineering and operations, content, technology and hardware, and so on. The company was founded on May 1, 1976, and is headquartered in New York, with regional offices in North America, Europe, Australia, the Middle East, and Asia Pacific.
Timothy R. Barakett is an Independent Director of KKR & Co. Inc., having joined the company’s Board of Directors on March 13, 2025, when he was appointed to strengthen governance and board independence. Before his board role at KKR, Barakett built a longstanding career in investment management as founder and CEO of TRB Advisors and earlier founded Atticus Capital, bringing deep financial and strategic expertise to his director duties. He holds a Bachelor of Arts in Economics from Harvard University and an MBA from Harvard Business School.
Insomniac Hedge Fund Guy Opinion:
KKR has quietly evolved from a classic private equity shop into a diversified alternative asset powerhouse with durable, fee-related earnings that deserve a higher multiple than old-school carry-dependent models. The integration of insurance capital through Global Atlantic is the masterstroke—permanent capital changes the game. It lowers volatility, stabilizes earnings, and gives them dry powder when others are scrambling.
The market periodically punishes KKR whenever exits slow or IPO windows shut. That’s short-term thinking. The real story is FRE compounding and insurance-driven asset growth. However, this is not a bargain-bin stock. At elevated multiples, you are paying for flawless execution and a cooperative credit cycle.
If capital markets thaw and distributions accelerate, earnings will snap back hard. If liquidity stays tight, fee-related earnings cushion the blow but don’t eliminate it.
KKR isn’t a lottery ticket. It’s a leveraged bet on long-term private market expansion wrapped in a semi-stable cash flow machine. At the right price, it’s institutional-grade compounding. At the wrong price, it’s optimism disguised as inevitability.
Not financial advice. Just one insomniac who’s seen what happens when liquidity disappears and when it floods back in.
Name: Todd Maclin
Position: Director
Transaction Date: 02-09-2026 Shares Bought: 10,000 shares an average price paid of $104.15 for Cost: $1,041,467
Company: Kimberly Clark Corp. (KMB)
Kimberly-Clark Corporation, through its subsidiaries, manufactures and markets personal care products in the United States. The company’s North America section sells disposable diapers, training and youth trousers, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom paper, and other brand names. The International Personal Care section offers disposable diapers, training and youth trousers, swimpants, baby wipes, and feminine and incontinence care products, as well as other brand names. The International Family Care and Professional category sells face and bathroom tissue, paper towels, napkins, wipes, and other brands. The corporation was founded in 1872 and is based in Dallas, Texas.
Todd Maclin has served as an Independent Director of Kimberly-Clark Corp. since 2019, when he was elected to the company’s Board of Directors at the annual shareholders’ meeting. Maclin joined Kimberly-Clark’s board with extensive leadership experience from his long career in banking, including senior executive roles at JP Morgan Chase & Co. At Kimberly-Clark, he contributes to the governance and compensation committees that shape the company’s strategy and oversight. He holds a Bachelor of Business Administration from the University of Texas at Austin.
Insomniac Hedge Fund Guy Opinion: KMB is a stable cash-flow machine with respectable margins and iconic brands, but its valuation doesn’t sufficiently discount execution risk from the Kenvue acquisition, integration complexity, and secular revenue stagnation. You’re buying defensive exposure and dividend yield, not dynamic growth. Execution on the healthcare pivot must be flawless for upside; otherwise, the current multiple leaves little margin of safety for value-oriented players.
Name: Bruce Caswell
Position: CEO & President
Transaction Date: 02-10-2026 Shares Bought: 3,175 shares an average price paid of $78.45 for Cost: $249,081
Company: Maximus Inc. (MMS)
Maximus, Inc. provides government services worldwide. The company operates in three segments. The Federal Services section provides business process services, eligibility and enrollment, outreach, and other services for federal health and human services programs, as well as clinical and technological solutions. The U.S. Services sector provides program eligibility support and enrollment; centralized multilingual customer contact centers; multichannel and digital self-service enrollment alternatives; application assistance; and person-centered independent evaluation services. The Outside the U.S. segment provides BPS and technology solutions to international governments, such as health and disability assessments, program administration for employment services, well-being solutions and other job seeker-related services, digitally enabled customer service, and modernization technologies. The company was founded in 1975 and is headquartered in McLean, Virginia.
Bruce Caswell has served as President of Maximus Inc. since October 2014 and has held the role of Chief Executive Officer since April 1, 2018. Since joining the company in 2004, he has held several senior leadership positions, overseeing all segments of the company’s business. Under his leadership, Maximus has focused on modernizing government service delivery and expanding its core capabilities. He holds a B.A. in economics from Haverford College and a master’s in public policy from the John F. Kennedy School of Government at Harvard University.
Insomniac Hedge Fund Guy Opinion:
Maximus is a bureaucratic cash machine embedded deep inside U.S. government health programs. The moat isn’t flashy — it’s incumbency, regulatory complexity, and the sheer pain of switching vendors. That stickiness creates durable, recurring revenue, but let’s not kid ourselves — this is a services contractor with capped margins, not a high-multiple tech rocket.
Five-year growth was boosted by pandemic programs; normalized growth should settle into the low single digits. Profitability is solid but unremarkable compared to peers like Booz Allen or Leidos. The appeal here is stability, not upside torque.
Recent insider buying suggests management believes budget fears may be overdone. Short interest is low — no meaningful bear narrative. A conservative DCF points to fair value around $90–$100. Below that, you’re getting paid for patience. Above it, you’re buying safety at full price.
Maximus isn’t exciting — it’s dependable. Own it for disciplined compounding, not hero returns. Not financial advice. Do your own work.
Name: Charles Alexander Mathis
Position: Director
Transaction Date: 02-11-2026 Shares Bought: 6,000 shares an average price paid of $35.20 for Cost: $211,230
Company: Scansource Inc. (SCSC)
ScanSource, Inc., distributes technology goods and solutions in the United States and globally. It operates in two segments: Specialty Technology Solutions and Intelisys & Advisory. The Specialty Technology Solutions section provides mobility and barcode solutions. The Intelisys & Advisory division provides connectivity and software-defined networking. This section assists channel sales partners in servicing a wide range of end users, including enterprises ranging in size from very small to enterprise. It supports a variety of industries, including manufacturing, warehouse and distribution, retail and e-commerce, hotel, transportation and logistics, government, education, and healthcare. ScanSource, Inc. was established in 1992 and is based in Greenville, South Carolina.
Charles Alexander Mathis has been a director at ScanSource Inc. since August 2021, when he was named to the company’s Board of Directors. Mathis formerly served as Chief Financial Officer of ScanSource from 2012 to 2016, after which he held executive finance positions at other companies, including SAIC. Most recently, he was appointed Lead Independent Director of ScanSource’s Board in January 2026 as part of board and committee restructuring. He has decades of financial leadership experience in technology and government services organizations and holds a B.A. from Wake Forest University and an M.B.A. from the University of Chicago.
Insomniac Hedge Fund Guy Opinion:
ScanSource is a classic under-the-radar compounder — boring, cyclical, and quietly improving its business mix. The shift toward recurring Intelisys commissions is the real story. It smooths earnings, boosts margins, and adds durability to what was once purely transactional distribution.
That said, this is still a thin-margin distributor exposed to economic cycles. No moat wide enough to brag about — just solid execution and disciplined capital allocation. Insider buying suggests management sees value near current levels, likely betting we’re close to a hardware cycle trough.
If you’re buying below intrinsic value with realistic 4–5% growth expectations, this can be a steady base hit. If you’re expecting multiple expansion fireworks, you’re in the wrong casino.
It’s not glamorous. It’s not disruptive. It’s a valuation discipline play.
Not financial advice — just one market veteran who knows distributors reward patience, not hype.
Name: Matthew Strobeck
Position: Director
Transaction Date: 02-13-2026 Shares Bought: 10,000 shares an average price paid of $23.96 for Cost: $239,586
Company: QuidelOrtho Corp. (QDEL)
QuidelOrtho Corporation offers diagnostic testing solutions. The company operates in four business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. The Labs business unit offers clinical chemistry laboratory instruments and tests that measure target compounds in bodily fluids for the evaluation of health testing products used to detect and monitor illness progression across a wide range of treatment fields, as well as specialty diagnostic solutions. The company’s products are sold directly to end consumers via a direct sales staff. Its operations span North America, Europe, the Middle East, Africa, China, and other regions. The company was established in 1979 and is based in San Diego, California.
Matthew Strobeck has been an independent director of QuidelOrtho Corp since 2018, joining the board following the merger of Quidel and Ortho Clinical Diagnostics and bringing his expertise in healthcare and life sciences investing and governance. In his role as a director, he has served on key board committees such as the Audit and Science & Technology Committees, assisting in the oversight of the company’s strategic, scientific, and financial elements. Matthew Strobeck earned a B.S. from St. Lawrence University, dual S.M. degrees from the Harvard University/MIT Health Sciences & Technology Program and the MIT Sloan School of Management, and a Ph.D. from the University of Cincinnati.
Insomniac Hedge Fund Guy Opinion:
QuidelOrtho is not a growth darling — it’s a post-pandemic digestion story with leverage. The company owns a respectable diagnostics platform with a sticky installed base and recurring consumables revenue, but COVID distorted everything. What looked like hyper-growth was temporary sugar. Now we’re left evaluating the real business underneath.
The investment thesis hinges on three variables: margin normalization, debt reduction, and stabilization of core diagnostic volumes. If management executes, this becomes a mid-single-digit grower with expanding operating leverage. If they don’t, it’s a value trap competing against global diagnostics titans with deeper pockets.
The current valuation reflects skepticism. Short interest isn’t extreme, but the market clearly doubts the pace of recovery. Insider buying at depressed levels suggests management believes the worst is priced in, but it’s not overwhelming conviction buying.
My DCF suggests modest upside assuming normalized margins and conservative growth. However, this is not a wide-moat compounder. It’s a restructuring and integration execution story.
For a disciplined investor, QDEL is a cyclical healthcare value play, not a secular growth machine. The margin of safety exists only if you believe management can restore profitability toward peer levels. Execution will determine whether this is a quiet turnaround winner — or just another COVID hangover casualty.
Name: David Bass
Position: EVP Engineering & CTO
Transaction Date: 02-09-2026 Shares Bought: 2,980 shares an average price paid of $23.47 for Cost: $69,941
Name: John J. Gavin Jr.
Position: Director
Transaction Date: 02-06-2026 Shares Bought: 5,000 shares an average price paid of $22.54 for Cost: $112,700
Name: Yakov Faitelson
Position: CEO, President, Chairman
Transaction Date: 02-09-2026 Shares Bought: 26,725 shares an average price paid of $22.41 for Cost: $598,907
Name: Avrohom J. Kess
Position: Director
Transaction Date: 02-06-2026 Shares Bought: 17,800 shares an average price paid of $22.29 for Cost: $396,762
Company: Varonis Systems Inc. (VRNS)
Varonis Systems, Inc. offers software solutions and services that use AI-powered technology to continuously locate and classify key data, remediate exposures, and detect advanced threats in North America, Europe, APAC, and the rest of the world. Varonis Data Security Platform, a Software-as-a-Service solution, includes data security posture management, data access intelligence, data discovery and classification, a discovery policy library, least privilege automation, data activity monitoring, data detection and response, and user and entity behavior analytics. It also offers protection packages for Microsoft 365, Windows & NAS, Hybrid, and cloud environments, as well as database and email security capabilities and on-premises subscription products. The company was established in 2004 and is based in Miami, Florida.
David Bass is the Executive Vice President of Engineering and Chief Technology Officer at Varonis Systems Inc., a role he has held since March 2018, when he was appointed to lead the company’s global engineering and technology strategy, including product development and quality assurance. He joined Varonis in 2005 and rose through engineering leadership roles, serving as Senior Vice President of Engineering from May 2014 through February 2018 before becoming EVP & CTO contributing to the company’s growth in data security and innovation. Under his leadership, Varonis’ engineering organization has produced numerous patented technologies in security, storage, networking, cloud computing, and machine learning.
John J. Gavin, Jr. has served as a Director of Varonis Systems, Inc. since 2013, when he was elected to the company’s Board of Directors and later designated Lead Independent Director, providing governance and financial oversight including chairing the Audit Committee. At Varonis, he brings more than four decades of financial and operational management experience from prior executive roles with technology and software firms, strengthening board leadership and strategic oversight. He received his undergraduate degree from Providence College, grounding his career in financial and business leadership.
Yakov Faitelson is the Chief Executive Officer, President, and Chairman of the Board of Directors of Varonis Systems, Inc. has served in these roles since 2004. He has been with the company since its founding, as the business was formed and structured around its leadership team. Under his leadership, Varonis has grown into a global data-security software provider built on technology he and co-founder Ohad Korkus conceived, and he has overseen strategy and execution across the company’s operations and product vision.
Avrohom J. Kess has served as an independent director of Varonis Systems, Inc. since January 2022, when he was elected to the company’s Board of Directors and joined its Compensation Committee, bringing legal and governance expertise to the cybersecurity software firm. Before joining Varonis’ board, Kess built a distinguished legal career, including as Vice Chairman and Chief Legal Officer of The Travelers Companies, a role he has held since December 2016, and previously as a partner and head of the Public Company Advisory Practice at Simpson Thacher & Bartlett LLP. He received his undergraduate degree from Brooklyn College and a law degree from New York University School of Law, grounding his professional background in legal and corporate governance.
Insomniac Hedge Fund Guy Opinion: Varonis has real tech and sticky renewals, but its valuation still seems priced for flawless SaaS expansion while profitability lags. Attractive on deep pullbacks, but you’re owning execution risk — not a free lunch.
Name: Peter D. Fitzsimmons
Position: President & CEO
Transaction Date: 02-05-2026 Shares Bought: 12,750 shares an average price paid of $19.68 for Cost: $250,879
Transaction Date: 02-03-2026 Shares Bought: 13,350 shares an average price paid of $18.80 for Cost: $251,017
Company: Monro Inc. (MNRO)
Monro, Inc. operates retail tire and vehicle service stores in the United States. It specializes in tire replacement and related services, automotive undercar repair, and routine maintenance for passenger automobiles, light trucks, and vans. Other products and services offered by the company include brakes, mufflers, and exhaust systems, as well as steering, drive train, suspension, and wheel alignment. It runs locations under the following brand names: Monro Auto Service and Tire Centers, Tire Choice Auto Service Centers, Mr. Tire Auto Service Centers, Car-X Tire & Auto, Tire Warehouse Tires for Less, Ken Towery’s Tire & Auto Care, Mountain View Tire & Auto Service, and Tire Barn Warehouse. The company was founded in 1957 and is based in Fairport, New York.
Peter Fitzsimmons has been President and Chief Executive Officer of Monro Inc. since March 2025, and he signed a formal employment agreement directly with the company in December 2025. He has over 30 years of senior management and advising expertise, having worked for a variety of retail and car repair organizations. He was previously a partner and managing director at AlixPartners, a global consulting firm, where he held client-focused leadership roles, advising companies and acting as an advisor, CEO, and CFO for clients undergoing significant transformation, turnaround, and operational improvement efforts. He graduated from Harvard College with a Bachelor of Arts and received his MBA from Dartmouth College’s Tuck School of Business.
Insomniac Hedge Fund Guy Opinion: Monro’s value proposition is complicated: a solid regional player with a narrow moat, stuck in a low-margin, transactional business. Recent strategic store closures and digital initiatives hint at improving profitability, and insider/activist buying — especially by a heavyweight like Icahn — suggests deep value belief. But Monro’s current market valuation seems to price in a smooth turnaround with expanding margins that aren’t yet proven. With high short interest and operational risk, this is a value/restructuring story, not a classic growth rock. The risk/reward demands discipline and a margin of safety; only those comfortable with execution risk and cyclicality should engage.
Name: Philip Austin Jr. Singleton
Position: Executive Chairman
Transaction Date: 02-11-2026 Shares Bought: 24,353 shares an average price paid of $12.63 for Cost: $307,501
Company: OneWater Marine Inc. (ONEW)
OneWater Marine Inc. is a recreational marine retailer in the United States. The company sells new and pre-owned recreational boats and yachts, as well as related nautical products, including parts and equipment. It also offers boat repair and maintenance services, as well as ancillary services including indoor and outdoor storage and marina services. In addition, the company offers boat financing, insurance, and extended service contracts for customers through third-party lenders and insurance providers. Furthermore, it rents out boats and personal watercraft. The company was founded in 2014 and is based in Buford, Georgia.
P. Austin Singleton has been the Executive Chairman of the Board of OneWater Marine Inc. since August 2025, overseeing the company’s strategic direction, stakeholder engagement, and shareholder value generation. Mr. Singleton previously held the positions of Chief Executive Officer and Director from April 2019 to August 2025, Chief Executive Officer of OneWater Marine from its establishment in 2014, and CEO of Singleton Marine, which merged with Legendary Marine to form OneWater Marine in 2006. He also served on OneWater Marine’s Board of Managers from its formation in 2006 until its initial public offering (IPO). He graduated from Auburn University with a degree in business and finance.
Insomniac Hedge Fund Guy Opinion:
OneWater Marine is a classic post-boom cyclical unwind. The company smartly scaled during the COVID marine surge, but now faces the hangover: higher rates, softer discretionary demand, and margin compression. This isn’t a structural growth compounder — it’s a rate-sensitive retailer with operating leverage.
The debate is simple: is the market pricing a cyclical trough or a permanent impairment? At normalized mid-cycle margins, shares appear undervalued. But this is not a “set it and forget it” stock. Timing and cycle discipline matter.
Insider buying suggests management believes the downturn is temporary. Elevated short interest reflects fear around inventory and consumer demand. Both sides have a case in the near term.
If you understand cyclicals and are willing to stomach volatility, ONEW could offer asymmetric upside off trough sentiment. If you want durable recurring revenue and moat-driven pricing power, this isn’t your horse.
Name: Ali Mazanderani
Position: Executive Chairman
Transaction Date: 02-09-2026 Shares Bought: 91,423 shares an average price paid of $4.36 for Cost: $398,604
Company: Lesaka Technologies Inc. (LSAK)
Lesaka Technologies, Inc. offers financial technology solutions and services through its platform in South Africa and around the world. The company provides merchant solutions such as merchant acquiring, integrated POS software and hardware for the hospitality industry, international money transfers, supplier-enabled payments, and prepaid solutions for airtime, internet, power, and gaming. It also offers low-cost EasyPay Everywhere transactional bank accounts, short-term personal loans, life and funeral insurance, and secure payout options; and Adumo, a payments and commerce enablement platform that offers payment processing and integrated software solutions. The company provides services to unbanked and underbanked consumers, small-to-medium and micro merchants, as well as corporate and government institutions such as banks, mobile network operators, and municipalities. The company was created in 1989 and has its headquarters in Johannesburg, South Africa.
Ali Mazanderani has been the Executive Chairman of Lesaka Technologies Inc. since February 1, 2024. He has been a director of the company since 2020, when he joined the Board and started contributing to its strategic fintech direction. He was appointed executive chairman on February 1, 2024, following his tenure as a non-executive director, and has since managed the company’s strategic plans and governance on the board. He holds multiple advanced degrees, including an MSc in Economics from the University of Oxford, an MSc in Economic History from the London School of Economics, an MBA from INSEAD, a master’s in business law from the University of St. Gallen, and a BCom in Economics from the University of Pretoria.
Insomniac Hedge Fund Guy Opinion: Lesaka is a juicy Southern African fintech story with a compelling mission — digital inclusion — and an increasingly diversified product stack. But let’s not dress it up like a Silicon Valley unicorn: margins are slim, past earnings were negative, and internal control gaps flagged in filings remain a red flag. That said, management’s aggressive M&A, positive adjusted EBITDA momentum, and insider buying suggest confidence that the pivot toward profitability and digital banking (via Bank Zero) will stick. The moat is real but narrow — susceptible to nimble competitors — and recurring revenue details are opaque. At current prices, there’s asymmetric upside if the growth narrative survives macro pressures and execution risks, but bulls are buying optionality on a turnaround, not a safe, cash-spinning fintech. This isn’t personalized advice — it’s raw market perspective from someone who’s seen fintech pivots win and flame out. Be sharp, watch execution, and respect the risks.